Technical Analysis for ZBIO - Zenas BioPharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 13.45 | -7.24% | -1.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -7.24% | |
| Hammer Candlestick | Bullish | -7.24% | |
| Lower Bollinger Band Walk | Weakness | -7.24% | |
| New 52 Week Low | Weakness | -7.24% | |
| Wide Bands | Range Expansion | -7.24% | |
| Below Lower BB | Weakness | -7.24% | |
| Down 3 Days in a Row | Weakness | -7.24% | |
| Down 4 Days in a Row | Weakness | -7.24% | |
| Down 5 Days in a Row | Weakness | -7.24% | |
| Oversold Stochastic | Weakness | -7.24% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 39 minutes ago |
| Down 5% | 39 minutes ago |
| 2x Volume Pace | about 1 hour ago |
| 1.5x Volume Pace | about 1 hour ago |
| Down 3% | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Zenas BioPharma, Inc. Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Immune System Antibodies Monoclonal Antibody Multiple Sclerosis Glycoproteins Systemic Lupus Erythematosus Immunoglobulin E Warm Autoimmune Hemolytic Anemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.2508 |
| 52 Week Low | 12.88 |
| Average Volume | 142,345 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 20.15 |
| 10-Day Moving Average | 18.92 |
| Average True Range | 2.28 |
| RSI (14) | 27.01 |
| ADX | 20.52 |
| +DI | 13.27 |
| -DI | 28.77 |
| Chandelier Exit (Long, 3 ATRs) | 19.42 |
| Chandelier Exit (Short, 3 ATRs) | 19.71 |
| Upper Bollinger Bands | 24.83 |
| Lower Bollinger Band | 15.48 |
| Percent B (%b) | -0.11 |
| BandWidth | 46.36 |
| MACD Line | -0.89 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.8242 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.83 | ||||
| Resistance 3 (R3) | 17.66 | 16.38 | 17.28 | ||
| Resistance 2 (R2) | 16.38 | 15.53 | 16.47 | 17.09 | |
| Resistance 1 (R1) | 15.44 | 15.01 | 14.80 | 15.61 | 16.90 |
| Pivot Point | 14.16 | 14.16 | 13.84 | 14.25 | 14.16 |
| Support 1 (S1) | 13.22 | 13.31 | 12.58 | 13.39 | 12.10 |
| Support 2 (S2) | 11.94 | 12.79 | 12.03 | 11.91 | |
| Support 3 (S3) | 11.00 | 11.94 | 11.73 | ||
| Support 4 (S4) | 11.17 |
